Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Home Page: www.amarincorp.com
AMRN Technical Analysis
Grand Canal Docklands
Dublin,
2
Ireland
Phone:
353 1 669 9020
Officers
Name | Title |
---|---|
Mr. Karim Mikhail | Pres, CEO & Director |
Dr. Steven B. Ketchum Ph.D. | Pres of R&D, Exec. VP and Chief Scientific Officer |
Mr. Jason M. Marks J.D. | Exec. VP, Chief Legal and Compliance Officer & Corp. Sec. |
Mr. Joseph T. Kennedy J.D. | Exec. VP of Strategic Initiatives & Gen. Counsel |
Mr. Aaron D. Berg | Exec. VP & Pres of U.S. |
Mr. Thomas Charles Reilly | CFO & Sr. VP |
Dr. David Keenan | Sr. VP of Technical Operations |
Ms. Lisa M. DeFrancesco | Sr. VP of Corp. Affairs & Investor Relations |
Alina Kolomeyer | Director of Communications |
Mr. Jordan Zwick | Sr. VP of Corp. Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 500 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.7969 |
Price-to-Sales TTM: | 1.1826 |
IPO Date: | 1993-04-01 |
Fiscal Year End: | December |
Full Time Employees: | 560 |